Circulation Research. 2001
Published online before print August 30, 2001,
doi: 10.1161/hh1801.096263
A more recent version of this article appeared on September 14, 2001
© 2001 American Heart Association, Inc.
Fc Receptor–Mediated Inhibitory Effect of Immunoglobulin Therapy on Autoimmune Giant Cell Myocarditis
Concomitant Suppression of the Expression of Dendritic Cells
Keisuke Shioji,
Chiharu Kishimoto
Shigetake Sasayama
From the Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Correspondence to Chiharu Kishimoto, MD, PhD, Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. E-mail kkishi{at}kuhp.kyoto-u.ac.jp
 |
Abstract
|
|---|
Abstract — In the present study, the mechanisms and importance
of the Fc portion of immunoglobulin in experimental giant cell
myocarditis were examined. Giant cell myocarditis was induced
in rats by immunization of porcine cardiac myosin. Human intact
immunoglobulin (1 g · kg
-1 · d
-1) or F(ab')
2 fragments
of human immunoglobulin (1 g · kg
-1 · d
-1) were
administered intraperitoneally daily on days 1 to 21. Intact
immunoglobulin administration significantly ameliorated myocarditis,
but F(ab')
2 fragments did not. The ribonuclease protection assay
revealed that therapy with intact immunoglobulin, but not F(ab')
2 fragments, suppressed the mRNA expressions of inflammatory and
proinflammatory cytokines. Immunohistochemical analysis showed
that therapy with intact immunoglobulin, but not F(ab')
2 fragments,
suppressed dendritic cell (DC) expression during both the early
and the subsequent fulminant phases. Moreover, the early treatment
of intact immunoglobulin until the 11th day or 14th day, when
the expression of DCs was completely suppressed, ameliorated
myocarditis. However, the late treatment of intact immunoglobulin
beginning on day 15, when the expression of DCs had already
been completed, failed to ameliorate the condition. An in vitro
study showed that intact immunoglobulin, but not F(ab')
2 fragments,
suppressed the lipopolysaccharide-induced interleukin-1ß
production associated with the downregulation of CD32 antigen
(Fc
receptor II) expression. Thus, intact immunoglobulin therapy
markedly suppressed myocarditis as a result of Fc receptor–mediated
anti-inflammatory action, and the suppression of the disease
was associated with the suppression of DCs, ie, the suppression
of the initial antigen-priming process in experimental giant
cell myocarditis.
Key Words: myocarditis • immunoglobulin • dendritic cells • cytokines • Fc receptors
|
Introduction
|
|---|
Giant cell myocarditis is frequently fatal. Because the disease
is occasionally associated with various autoimmune diseases,
autoimmune mechanisms were suggested to be involved in its pathogenesis.
1 The therapeutic efficacy of high-dose immunoglobulin has been
reported in inflammatory and autoimmune diseases, eg, Kawasaki
disease,
2 idiopathic thrombocytopenic purpura,
3 and peripartum
cardiomyopathy.
4 We have previously reported that immunoglobulin
therapy suppresses acute viral myocarditis as a result of an
anti-viral effect, an anti-inflammatory effect, and the improvement
of extracellular matrix changes.
5,6 Most recently, a novel mechanism
of action of immunoglobulin was proposed to be due to anti-inflammatory
activities through the inhibitory Fc receptors (FcRs).
7
It has been suggested that T-cell–mediated autoimmune diseases are the result of inappropriate antigen presentation of either a self-antigen or an antigen with the capacity to mimic a self-antigen in the peripheral lymphoid tissues.8 In fact, immunosuppressive agents, such as 15-deoxyspergualin, FK-506, and leflunomide, were confirmed to be effective in the suppression of the initial antigen-priming process in experimental autoimmune myocarditis.9–11 Dendritic cells (DCs) are specialized antigen-presenting cells (APCs) with FcRs that possess the capacity to activate naive T cells.12 Accordingly, DCs appear to play an important role during the initial antigen-priming process of myocarditis.11,13 Therefore, to clarify the FcR-mediated effects, we investigated the effects of immunoglobulin on autoimmune giant cell myocarditis with the analyses of immunologic behaviors of DCs and myocardial cytokines.
|
Materials and Methods
|
|---|
In Vivo Study
Immunization
Autoimmune myocarditis was induced as previously described.
14 Six- to 7-week-old Lewis rats (Shimizu Laboratory Supplies Co,
Ltd) were injected subcutaneously in their foot pads with porcine
cardiac myosin (1 mg/mL M0531, Sigma Chemical Co) mixed with
Freund’s complete adjuvant (FCA) supplemented with
Mycobacterium tuberculosis H37Ra (No. 3113-60, DIFCO) on days 1 and 7.
Immunoglobulin Treatment
Experiment I
In the rats immunized with porcine myosin or FCA, intact immunoglobulin (Venoglobulin-IH, a polyethylene glycol–treated human immunoglobulin, Welfide Corp) or F(ab')2 fragments (Gamma-Venin, Aventis Corp) of human immunoglobulin were administered intraperitoneally daily at a dose of 1 g · kg-1 · d-1 from day 1 to day 15 [intact immunoglobulin and myosin, n=6; F(ab')2 fragments and myosin, n=4] and to day 21 [intact immunoglobulin and myosin, n=13; intact immunoglobulin and FCA alone, n=4; F(ab')2 fragments and myosin, n=10; F(ab')2 fragments and FCA alone, n=4]. As determined from previous studies,2,3,5 the dose used was 1 g · kg-1 · d-1. Immunoglobulin antigenicity between different species did not appear to be a problem.5,6,15 In addition, both agents have the same chemical structure as the Fab portion of immunoglobulin. Littermate controls were injected with PBS intraperitoneally and killed on day 15 (myosin, n=6; FCA alone, n=3) or day 21 (myosin, n=16; FCA alone, n=4).
Experiment II
To clarify the importance of the suppression of the initial self-antigen process by immunoglobulin treatment on the basis of the findings of experiment I, in which the expression of DCs, the initiators of immune responses, reached maximum at approximately day 15, experiment II was conducted.
Early Treatment
This protocol aimed to suppress the initial self-antigen–priming process during the course of the disease. That is, intact immunoglobulin was administered daily to the rats immunized with myosin at the same dose as given in experiment I from day 1 to day 8 (n=5), to day 11 (n=5), and to day 14 (n=4), and the rats were killed on day 21. Control rats were injected with PBS from day 1 to day 8 (n=7), to day 11 (n=6), and to day 14 (n=6), and the rats were killed on day 21. Two rats in each group were also killed on day 8, day 11, and day 14 for the pathological examination.
Late Treatment
This protocol aimed to investigate the effects of intact immunoglobulin on the disease severity after completion of the initial self-antigen–priming process. That is, intact immunoglobulin was administered daily to the rats immunized with myosin at the same dose as in experiment I from day 15 to day 21, and the rats were killed on day 21 (n=8). Control rats were injected with PBS during these periods and killed on day 21 (n=7).
Histopathology
At euthanasia, macroscopic findings and pericardial effusion were graded on a scale of 0 to 2, as previously described.14 Microscopic findings for cellular infiltration and myocardial necrosis were graded on a scale of 0 to 3, as previously described.14
Immunohistochemistry
Immunohistochemistry for surface markers was performed, as previously described.13 The primary antibodies (Serotec) used were as follows: OX62 antibody to recognize an integrin or integrin-like molecule present on DCs and 
T cells,16 V65 antibody to specifically detect T cells,17 OX6 antibody to recognize major histocompatibility complex (MHC) class II–expressing cells, including DCs, monocytes, and B lymphocytes,13 ED1 antibody to detect inflammatory macrophages,13 ED2 antibody to detect tissue macrophages,13 W3/25 antibody to detect helper T lymphocytes and macrophages,13 and OX8 antibody to detect cytotoxic/suppressor T lymphocytes.13 W3/25 antibody is regarded as being directed against the rat homologue of CD4.
Ribonuclease Protection Assay
mRNA was extracted from the myocardium by using TRIzol (GIBCO-BRL), and cytokine mRNA levels were measured with RiboQuant Multi-Probe template sets, In Vitro transcription kits, and ribonuclease protection assay (RPA) kits (PharMingen) according to the PharMingen/RiboQuant protocol.18 The NIH Image system was used to quantify the pixel intensity of macrophage inhibitory factor (MIF) cytokine bands, which were divided by the intensities in their L32 bands in the same lanes for normalization.
In Vitro Study
U937 cells, human monoblast cells bearing FcRs,19 were stimulated with 10 ng/mL lipopolysaccharide (LPS) of Escherichia coli (Sigma). Forty-eight hours later, interleukin (IL)-1ß in the medium was assayed by using antibody-sandwich ELISA.
For the analysis of surface markers, the collected cells were incubated with an appropriate dilution of primary antibodies: CD16 (FcRIII, Ancell), CD32 (FcRII, Serotec), and CD64 (FcRI, Ancell). They were incubated with the fluorescein isothiocyanate–conjugated F(ab')2 secondary antibody (Serotec), and 1x104 cells per trial were analyzed with a FACScan cytometer (Becton Dickinson) by use of CELLQuest.
Intact human immunoglobulin or the F(ab')2 fragments were added to the medium 30 minutes before LPS stimulation. The doses of the agents used in the present study were derived from the methods of Andersson and Andersson.20
Statistical Analysis
Values were expressed as the mean±SD. Statistical analyses of the data were performed by 1-way ANOVA and were reanalyzed with the Fisher protected least significant difference test to characterize significant differences between groups in the in vitro study and experiment I; the Student t test was used in experiment II. A value of P<0.05 was considered statistically significant.
|
Results
|
|---|
FcR-Mediated Inhibitory Effect and Suppression of Expression of DCs by Immunoglobulin Treatment In Vivo (Experiment I)
Histopathology and Heart Weight/Body Weight Ratio
None of the rats died throughout the entire period. On day 15,
the hearts showed a normal appearance macroscopically except
for one of six rats. However, several infiltrating inflammatory
cells surrounding small vessels among cardiomyocytes were observed
microscopically in all the rats (
Figure 1A). In rats treated
with intact immunoglobulin, no evidence of myocarditis was shown
on day 15. In rats treated with F(ab')
2 fragments, several infiltrating
inflammatory cells were observed microscopically.
Table 1 shows
histological analysis for experiment I.
View larger version (191K):
[in this window]
[in a new window]
|
Figure 1. Representative histopathology and immunohistochemistry for surface markers of myocardial infiltrating cells. A and B, Hematoxylin and eosin (H-E) staining on tissues from rats immunized with myosin and injected with PBS. On day 15, several infiltrating inflammatory cells (arrow) are observed (A). On day 21, extensive injury of myocytes with various kinds of inflammatory changes, including multinucleated giant cells (arrow and inset), is observed (B). Original magnification x100 (inset x320). C through F, Immunohistochemistry for OX6 (C), ED1 (D), ED2 (E), and W3/25 (F) on tissues from rats immunized with myosin, injected with PBS, and killed on day 15. Almost of all the inflammatory cells in panel A show immunoreactivity for anti-OX6 antibody (C). ED1-positive cells (D) and ED2-positive cells (E) were observed, but only a few cells showed very weak immunoreactivity for anti-W3/25 antibody (F). Arrows indicate positive staining cells. Original magnification x200. All sections are serial.
|
|
On day 21, 11 of 16 hearts showed severe and diffuse discolored myocarditis with massive pericardial effusion. Extensive injury of the myocytes with inflammatory changes and multinucleated giant cells were observed microscopically (Figure 1B). Treatment with intact immunoglobulin, but not F(ab')2 fragments, reduced the severity of the disease, as assessed by measuring the heart weight/body weight ratio and histological scores.
Immunohistochemistry of Surface Markers
On day 15, in rats immunized with myosin and injected with PBS, almost of all the infiltrating inflammatory cells showed immunoreactivity for anti-OX6 antibody (Figure 1C). ED1-positive cells (Figure 1D) and ED2-positive cells (Figure 1E) were observed, but only a few cells showed very weak immunoreactivity for anti-W3/25 (Figure 1F) or anti-OX8 (data not shown) antibody. Several OX62-positive cells infiltrated into the perivascular cardiac tissue (Figure 2A); all were DCs, because no anti–V65-positive cells were detected (data not shown). Accordingly, MHC class II–positive myeloid cells, including DCs, play a pivotal role during the early phase. Treatment with intact immunoglobulin (Figures 2B and 3A), but not F(ab')2 fragments (Figures 2C and 3A), reduced the number of OX62-positive cells.
View larger version (36K):
[in this window]
[in a new window]
|
Figure 3. Quantitative analysis of OX62- and OX6-positive infiltrating cells. OX62 antibody recognizes DCs and T cells. OX6 antibody recognizes DCs, monocytes, and B lymphocytes. A and B, Quantitative analysis of OX62. Controls indicate rats immunized with myosin and injected with PBS; F(ab`)2 fragment, rats immunized with myosin and treated with F(ab`)2 fragments; intact, rats immunized with myosin and treated with intact immunoglobulin. Panel A shows results for rats killed on day 15. Treatment with intact immunoglobulin suppressed the expression of OX62-positive cells compared with no treatment (controls) and treatment with F(ab`)2 fragments. Treatment with F(ab`)2 fragments did not suppress the expression of OX62-positive cells compared with no treatment (controls). *P<0.05. Panel B shows results for rats killed on day 21. Treatment with intact immunoglobulin suppressed the expression of OX62-positive cells compared with no treatment (controls), but treatment with F(ab`)2 fragments did not suppress the expression of OX62-positive cells compared with no treatment (controls). *P<0.05. C, Quantitative analysis of OX6. Day 15 indicates rats immunized with myosin, injected with PBS, and killed on day 15; day 21, rats immunized with myosin, injected with PBS, and killed on day 21. The number of OX6-positive cells is higher on day 21 than on day 15. The ratio of OX62-positive cells to OX6-positive cells in the heart immunized with myosin and injected with PBS on day 15 and day 21 was 0.46±0.23 and 0.042±0.029, respectively. Accordingly, in the natural course of the disease, the proportion of OX62-positive cells in the MHC class II–expressing cells is decreased during the fulminant phase (day 21) compared with the early phase (day 15). Quantitative analyses were performed by counting all positively stained cells in 0.25x0.25-mm fields. Seven distinct fields per rat were counted. The number of rats was 3 for all groups. The values are expressed as mean±SD.
|
|
On day 21, OX62-positive cells were scattered in inflammatory foci (Figure 2D), and only a few V65-positive cells were detected (data not shown). The number of OX6-positive cells was markedly increased (Figure 3C). The ratio of OX62-positive cells to OX6-positive cells in the heart immunized with myosin and injected with PBS on day 15 and day 21 was 0.46±0.23 and 0.042±0.029, respectively. Accordingly, in the natural course of the disease, the proportion of OX62-positive cells in the MHC class II–expressing cells was decreased during the fulminant phase (day 21) compared with the early phase (day 15). Treatment with intact immunoglobulin (Figures 2E and 3B), but not F(ab')2 fragments (Figures 2F and 3B), reduced the numbers of OX62-positive cells.
Ribonuclease Protection Assay
On day 15 (Figure 4A), the mRNA expression of cytokines in intact hearts immunized with FCA alone was only for MIF, which is released as a proinflammatory cytokine.21 In rats immunized with myosin and injected with PBS, mRNA expression of MIF was enhanced (by 3.1-fold relative to intact hearts). However, in rats immunized with myosin and treated with intact immunoglobulin, the mRNA expression of MIF was not enhanced (1.1-fold relative to intact hearts).
View larger version (67K):
[in this window]
[in a new window]
|
Figure 4. RPA for mRNAs of Th1, Th2, and proinflammatory cytokines. A, Rats killed on day 15. In rats immunized with myosin and injected with PBS, mRNA expression of MIF was enhanced by 3.1-fold relative to intact hearts. However, treatment with intact immunoglobulin reduced the mRNA expression of MIF (1.1-fold relative to intact hearts). B, Rats killed on day 21. In rats immunized with myosin and injected with PBS, mRNAs of Th1 cytokines (such as IL-18), Th2 cytokines (such as IL-6 and IL-10), and proinflammatory cytokines (such as MIF, IL-1 , IL-1ß, and IL-1Ra) were markedly upregulated compared with intact heart mRNAs. Treatment with immunoglobulin, but not F(ab`)2 fragments, reduced the expression of cytokine mRNAs. IFN- indicates interferon-. L32 is a housekeeping gene. A representative finding of 3 distinct experiments is shown.
|
|
On day 21 (Figure 4B), in intact hearts immunized with FCA alone and injected with PBS, mRNA expression of cytokines was detected only for MIF. In rats immunized with myosin and injected with PBS, mRNAs of Th1 cytokines (such as IL-18), Th2 cytokines (such as IL-6 and IL-10), and proinflammatory cytokines (such as MIF, IL-1, IL-1ß, and IL-1Ra) were markedly upregulated, and mRNA expression of IL-12p35, IL-12p40, and interferon- was slightly upregulated. Treatment with immunoglobulin, but not F(ab')2 fragments, reduced the expression of cytokine mRNAs.
FcR-Mediated Inhibitory Effect of Immunoglobulin In Vitro
IL-1ß production was increased by LPS stimulation in U937 cells (0.7±0.8 pg/mL for controls, n=4; 9.1±1.5 pg/mL for LPS, n=4 [P<0.01]). Intact immunoglobulin (7.0±1.4 pg/mL for 0.6 mg, n=4 [P=NS]; 5.5±1.7 pg/mL for 6.0 mg, n=4 [P<0.05]), but not F(ab')2 fragments (8.9±1.5 pg/mL for 0.4 mg, n=4 [P=NS]; 8.8±5.0 pg/mL for 4.0 mg/mL, n=4 [P=NS]), suppressed LPS-induced IL-1ß production in a dose-dependent manner (Figure 5A).
View larger version (25K):
[in this window]
[in a new window]
|
Figure 5. Effects of immunoglobulin on LPS-induced IL-1ß production and CD32 (FcRII) expression. A, Analysis of IL-1ß production. IL-1ß production was increased by LPS stimulation in U937 cells. Intact immunoglobulin, but not F(ab`)2 fragments, suppressed LPS-induced IL-1ß production in a dose-dependent manner. The values are expressed as mean±SD of 4 independent experiments. *P<0.05 vs IL-1ß production stimulated with LPS without intact immunoglobulin treatment. B, Representative flow cytometric analysis of CD32 expression. In graph a, CD32 was expressed in nonstimulated U937 cells (dotted line, MFI 100%). In graph b, CD32 expression was upregulated by LPS stimulation (solid line, MFI 148%). In graph c, LPS-induced CD32 expression (solid line) was downregulated by intact immunoglobulin treatment (heavy solid line, MFI 109%). In graph d, LPS-induced CD32 expression (solid line) was not changed by F(ab`)2 fragments (heavy solid line, MFI 123%). Background fluorescence intensity (shadow area) was obtained through the procedure without primary antibodies. The x-axis shows fluorescence intensity (arbitrary units). The y-axis shows cell number. Experimental values are expressed as the percentage of MFI relative to the control value. The findings were similar and are representative of 4 separate experiments. FL1-H indicates fluorescence intensity.
|
|
In U937 cells, CD32 was expressed and upregulated by LPS stimulation (Figure 5B). The expression of CD16 and CD64 was not varied from the baseline at any time point (data not shown). Intact immunoglobulin downregulated LPS-induced CD32 expression, and the median fluorescence intensity (MFI) relative to the control was decreased by the treatment (143±26% for LPS, n=4; 101±18% for LPS plus intact immunoglobulin, n=4 [P<0.05]). However, the LPS-induced CD32 expression was not changed by the treatment of F(ab')2 fragments [143±26% for LPS, n=4; 125±11% for LPS plus F(ab')2 fragments, n=4 (P=NS)].
Importance of Suppression of Initial Self-Antigen Priming Process by Intact Immunoglobulin Treatment (Experiment II)
Early Treatment
The treatment from day 1 to day 8 failed to decrease the severity of myocarditis (Table 2). Treatment with intact immunoglobulin from day 1 to both day 11 and day 14 decreased the severity of myocarditis, as assessed by measuring the heart weight/body weight ratio and histological scores. On day 8, OX62-positive cells were rarely detected in rats injected with PBS or in rats treated with intact immunoglobulin. On day 11, only a few OX62-positive cells had infiltrated the cardiomyocytes in rats injected with PBS but not the rats treated with intact immunoglobulin. On day 14, several OX62-positive cells were observed among cardiomyocytes in rats injected with PBS but not in rats treated with intact immunoglobulin. Accordingly, the early treatment of intact immunoglobulin from day 1 to day 11 or day 14, but not day 8, suppressed the expression of DCs, ie, the initial antigen-priming process, leading to the suppression of myocarditis.
Late Treatment
Treatment with intact immunoglobulin did not decrease the severity of myocarditis (Table 2). Thus, the late treatment after the completion of DC expression did not cause a reduction in the severity of myocarditis.
|
Discussion
|
|---|
In the present study, it was shown that intact immunoglobulin,
but not F(ab')
2 fragments, markedly suppressed both the severity
of the disease and cytokine mRNA expression in experimental
giant cell myocarditis in vivo. Intact immunoglobulin, but not
F(ab')
2 fragments, suppressed LPS-induced IL-1ß production
associated with downregulation of CD32 expression in U937 cells
in vitro. Accordingly, FcR-mediated inhibitory effects actually
play an important role in the reduction of inflammatory cytokine
production in vitro and in vivo. In addition, intact immunoglobulin,
but not F(ab')
2 fragments, suppressed the DC expression during
both the early and fulminant phases in vivo. An additional experiment
confirmed that the suppression of DC expression during the early
phase of the disease, when DCs operate actively, caused a reduction
in myocarditis. The effect of immunoglobulin may be associated
with the suppression of the expression of DCs, ie, the suppression
of the initial antigen-priming process in experimental giant
cell myocarditis.
FcRs act as trigger molecules for inflammatory, allergic, endocytic, and inhibitory activities of immune effector cells.7,22 It has been reported that F(ab')2 fragments do not ameliorate experimental allergic encephalomyelitis in rats15 and that the anti-inflammatory activity of immunoglobulin is mediated through the inhibitory FcR.7 In the present study, an in vivo study confirmed that intact immunoglobulin administration, but not the administration of F(ab')2 fragments, completely suppressed the severity of the disease and the mRNA expression of cytokines (Figure 4). An in vitro study showed that intact immunoglobulin, but not F(ab')2 fragments, suppressed LPS-induced the IL-1ß production associated with the downregulation of CD32 (FcRII) expression. It is suggested that mRNA expression of cytokines may be blocked not only by anti-cytokine antibodies included in immunoglobulin used in the present study but also by the anti-inflammatory action mediated through the inhibitory FcR. The former possibility may be slight, because F(ab')2 fragments did not suppress mRNA expression of cytokines, which theoretically may possess anti-cytokine antibodies. We confirmed that the anti-inflammatory action of intact immunoglobulin in murine myocarditis induced by encephalomyocarditis virus was due to the reduction of the plasma level of interferon- and soluble intercellular adhesion molecule-1 but not to antiviral effects.6 Accordingly, the present study added further information that intact immunoglobulin treatment suppressed not only viral myocarditis but giant cell myocarditis by the anti-inflammatory action.
The present study provided evidence that almost of all the infiltrating inflammatory cells were MHC class II–positive myeloid cells, including DCs during the early phase. The proportion of DCs in the MHC class II–expressing cells was higher during the early phase compared with during the fulminant phase (Figure 3). DCs are functionally specialized APCs and efficient stimulators of B and T cells. Mature DCs express high MHC class II molecules that are 10- to 100-fold greater on DCs than on other APCs, such as B cells and monocytes.8,12 Intact immunoglobulin administration, but not the administration of F(ab')2 fragments, may suppress the activation of DCs because immature DCs are well equipped to capture antigens and have antigen-capturing Fc and Fc
receptors12; ie, exogenous native and intact immunoglobulin may bind to FcRs on DCs and prevent internalization of the antigen, and as a result, intact immunoglobulin with the Fc portion may prevent DCs from processing antigens to form MHC peptide complexes. The results of experiment II confirmed that the early treatment of immunoglobulin by the time DCs infiltrated to cardiomyocytes caused a reduction in myocarditis. Accordingly, the effect of immunoglobulin may be associated with the suppression of the initial antigen-priming process in experimental giant cell myocarditis.
We have previously reported that immunoglobulin suppresses coxsackievirus B3 myocarditis by an antiviral antibody included in the agent.5 However, immunoglobulin treatment failed to ameliorate myocarditis in an Intervention in Myocarditis and Acute Cardiomyopathy With Immune Globulin (IMAC) trial of human myocarditis.23 One reason may be that patients with dilated cardiomyopathy with noninflammatory causes occupied a large part of that trial. From the present findings, it may be that immunoglobulin therapy, if it is initiated early, is effective against human giant cell myocarditis, a disease with no present effective therapy other than transplantation.1 In conclusion, the present study provided evidence that intact immunoglobulin therapy markedly suppressed myocarditis because of the FcR-mediated anti-inflammatory action and the concomitant suppression of the initial antigen-priming process in experimental autoimmune myocarditis. The findings of the present study may yield important insights into both the clinical use of this therapy for human immune or autoimmune myocarditis and the future studies of FcR-mediated therapy for immune or autoimmune diseases.
|
Acknowledgments
|
|---|
This study was supported in part by research grants from the
Conference on Coronary Artery Disease, Japanese Education of
Science and Welfare (Nos. 08877110 and 0947016), the Kanae Shinyaku
Foundation, and Japan Cardiovascular Research Foundation. We
thank Drs Hajime Nakamura and Junji Yodoi, Institute for Virus
Research, Kyoto University, for helpful discussions and critical
comments on the manuscript.
Received November 27, 2000;
accepted July 19, 2001.
|
References
|
|---|
1.
Cooper LT, Berry GJ, Shabetai R, for the Multicenter Giant Cell Myocarditis Study Group Investigators. Idiopathic giant-cell myocarditis: natural history and treatment.
N Engl J Med. 1997;336:1860–1866.
2.
Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. . 1991; 324: 1633–1639.[Abstract]
3.
George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. . 1996; 88: 3–40.[Medline]
4.
Bozkurt B, Villaneuva FS, Holubkov R, Tokarczyk T, Alvarez RJ Jr, MacGowan GA, Murali S, Rosenblum WD, Feldman AM, McNamara DM. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol. . 1999; 34: 177–180.[Medline]
5.
Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model: antiviral and anti-inflammatory effects. Circulation. . 1995; 92: 1604–1611.[Abstract/Full Text]
6.
Kishimoto C, Takamatsu N, Kawamata H, Shinohara H, Ochiai H. Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change. J Am Coll Cardiol. . 2000; 36: 1979–1984.[Medline]
7.
Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. . 2001; 291: 484–486.[Abstract/Full Text]
8.
Ludewig B, Odermatt B, Ochsenbein AF, Zinkernagel RM, Hengartner H. Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev. . 1999; 169: 45–54.[Medline]
9.
Kodama M, Zhang S, Hanawa H, Saeki M, Inomata T, Suzuki K, Koyama S, Shibata A. Effects of 15-deoxyspergualin on experimental autoimmune giant cell myocarditis of the rat. Circulation. . 1995; 91: 1116–1122.[Abstract/Full Text]
10.
Hanawa H, Kodama M, Zhang S, Izumi T, Shibata A. An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. Clin Immunol Immunopathol. . 1992; 62: 321–326.[Medline]
11.
Dimitrijevic M, Milenkovic M, Milosavljevic P, Colic M. Effects of leflunomide on experimental autoimmune myocarditis with special reference to the dendritic cells. Transplant Proc. . 1998; 30: 4149–4150.[Medline]
12.
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. . 1998; 392: 245–252.[Medline]
13.
Suzuki K. A histological study on experimental autoimmune myocarditis with special reference to initiation of the disease and cardiac dendritic cells. Virchows Arch. . 1995; 426: 493–500.[Medline]
14.
Shioji K, Kishimoto C, Nakayama Y, Sasayama S. Strain difference in rats with experimental giant cell myocarditis. Jpn Circ J. . 2000; 64: 283–286.[Medline]
15.
Pashov A, Dubey C, Kaveri SV, Lectard B, Huang YM, Kazatchkine MD, Bellon B. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol. . 1998; 28: 1823–1831.[Medline]
16.
Brenan M, Puklavec M. The MRC OX-62 antigen: a useful marker in the purification of rat veiled cells with the biochemical properties of integrin. J Exp Med. . 1992; 175: 1457–1465.[Abstract]
17.
Kühnlein P, Park JH, Herrmann T, Elbe A, Hünig T. Identification and characterization of rat / T lymphocytes in peripheral lymphoid organs, small intestine, and skin with a monoclonal antibody to a constant determinant of / T cell receptor. J Immunol. . 1994; 153: 979–986.[Abstract]
18.
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. . 1998; 187: 875–883.[Abstract/Full Text]
19.
De SK, Venkateshan CN, Seth P, Gajdusek DC, Gibbs CJ. Adenovirus-mediated human immunodeficiency virus-1 Nef expression in human monocytes/macrophages and effect of Nef on downmodulation of Fc receptors and expression of monokines. Blood. 1998;91:2108–2117.
20.
Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology. . 1990; 71: 372–376.[Medline]
21.
Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donnelly T, Bucala R. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA. . 1996; 93: 7849–7854.[Abstract]
22.
Deo YM, Graziano RF, Repp R, van de Winkel JG. Clinical significance of IgG Fc receptors and FcR-directed immunotherapies. Immunol Today. . 1997; 18: 127–135.[Medline]
23.
McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. . 2001; 103: 2254–2259.[Abstract/Full Text]
This article has been cited by other articles:
|
|
|
|
 
P. Zhang, C. J. Cox, K. M. Alvarez, and M. W. Cunningham
Cutting Edge: Cardiac Myosin Activates Innate Immune Responses through TLRs
J. Immunol.,
July 1, 2009;
183(1):
27 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. HooKim, S. deRoux, A. Igbokwe, A. Stanek, J. Koo, J. Hsu, M. R. Pincus, and M. H. Bluth
IgG Anti-Cardiomyocyte Antibodies in Giant Cell Myocarditis
Ann. Clin. Lab. Sci.,
January 1, 2008;
38(1):
83 - 87.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-a. Okabe, K. Shimada, M. Hattori, T. Murayama, M. Yokode, T. Kita, and C. Kishimoto
Swimming reduces the severity of atherosclerosis in apolipoprotein E deficient mice by antioxidant effects
Cardiovasc Res,
June 1, 2007;
74(3):
537 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Staudt, P. Eichler, C. Trimpert, S. B. Felix, and A. Greinacher
Fc{gamma} Receptors IIa on Cardiomyocytes and Their Potential Functional Relevance in Dilated Cardiomyopathy
J. Am. Coll. Cardiol.,
April 24, 2007;
49(16):
1684 - 1692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kishimoto
A Novel Approach to the Suppression of Atherosclerosis by Fc{gamma} Receptor Blockade
Circ. Res.,
November 24, 2006;
99(11):
1154 - 1155.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hernandez-Vargas, G. Ortiz-Munoz, O. Lopez-Franco, Y. Suzuki, J. Gallego-Delgado, G. Sanjuan, A. Lazaro, V. Lopez-Parra, L. Ortega, J. Egido, et al.
Fc{gamma} Receptor Deficiency Confers Protection Against Atherosclerosis in Apolipoprotein E Knockout Mice
Circ. Res.,
November 24, 2006;
99(11):
1188 - 1196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kishimoto, K. Shioji, and Z. Yuan
Fc{gamma}IIB and Cardiovascular Inflammatory Disease
Circ. Res.,
February 17, 2006;
98(3):
e26 - e26.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nimata, T.-a. Okabe, M. Hattori, Z. Yuan, K. Shioji, and C. Kishimoto
MCI-186 (edaravone), a novel free radical scavenger, protects against acute autoimmune myocarditis in rats
Am J Physiol Heart Circ Physiol,
December 1, 2005;
289(6):
H2514 - H2518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z Yuan, Y Liu, Y Liu, J Zhang, C Kishimoto, Y Wang, A Ma, and Z Liu
Cardioprotective effects of peroxisome proliferator activated receptor {gamma} activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor {kappa}B blockade
Heart,
September 1, 2005;
91(9):
1203 - 1208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Yuan, M. Nimata, T.-a. Okabe, K. Shioji, K. Hasegawa, T. Kita, and C. Kishimoto
Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure
Am J Physiol Heart Circ Physiol,
September 1, 2005;
289(3):
H1147 - H1152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shioji, Z. Yuan, T. Kita, and C. Kishimoto
Immunoglobulin treatment suppressed adoptively transferred autoimmune myocarditis in severe combined immunodeficient mice
Am J Physiol Heart Circ Physiol,
December 1, 2004;
287(6):
H2619 - H2625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Liu, H. Nakamura, K. Shioji, M. Tanito, S.-i. Oka, M. K. Ahsan, A. Son, Y. Ishii, C. Kishimoto, and J. Yodoi
Thioredoxin-1 Ameliorates Myosin-Induced Autoimmune Myocarditis by Suppressing Chemokine Expressions and Leukocyte Chemotaxis in Mice
Circulation,
September 7, 2004;
110(10):
1276 - 1283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Yuan, K. Shioji, Y. Kihara, H. Takenaka, Y. Onozawa, and C. Kishimoto
Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property
Am J Physiol Heart Circ Physiol,
January 1, 2004;
286(1):
H83 - H90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Yuan, Y. Liu, Y. Liu, J. Zhang, C. Kishimoto, Y. Wang, A. Ma, and Z. Liu
Peroxisome proliferation-activated receptor-{gamma} ligands ameliorate experimental autoimmune myocarditis
Cardiovasc Res,
September 1, 2003;
59(3):
685 - 694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Yuan, C. Kishimoto, H. Sano, K. Shioji, Y. Xu, and M. Yokode
Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion
Am J Physiol Heart Circ Physiol,
July 11, 2003;
285(2):
H899 - H906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Staudt, M. Bohm, F. Knebel, Y. Grosse, C. Bischoff, A. Hummel, J. B. Dahm, A. Borges, N. Jochmann, K. D. Wernecke, et al.
Potential Role of Autoantibodies Belonging to the Immunoglobulin G-3 Subclass in Cardiac Dysfunction Among Patients With Dilated Cardiomyopathy
Circulation,
November 5, 2002;
106(19):
2448 - 2453.
[Abstract]
[Full Text]
[PDF]
|
|
|
Top
Abstract
Introduction
